Live News Reader

Some of the articles presented on this website are accessed through RSS feeds from third-party sources that are not necessarily part of the Histiocytosis Association. While we try to select appropriate feeds to prevent objectionable content from being displayed, the presence of any article does not indicate endorsement or recommendation by the Histiocytosis Association.

If you know of a histio-related article that isn't shown here, please send the article to outreach@histio.org.

Erdheim-Chester disease - Google News
This RSS feed URL is deprecated
This RSS feed URL is deprecated, please update. New URLs can be found in the footers at https://news.google.com/news
Friday, February 23, 2018 5:33:14 AM

FDA approves first treatment for certain patients with Erdheim-Chester Disease, a rare blood cancer - FDA.gov

Medscape

FDA approves first treatment for certain patients with Erdheim-Chester Disease, a rare blood cancer
FDA.gov
The U.S. Food and Drug Administration today expanded the approval of Zelboraf (vemurafenib) to include the treatment of certain adult patients with Erdheim-Chester Disease (ECD), a rare cancer of the blood. Zelboraf is indicated to treat patients whose ...
First Tx for Erdheim-Chester Disease, a Rare Blood Cancer
First-Ever FDA Approval for Erdheim-Chester Disease
Genentech's Zelboraf Gets FDA Approval in BRAF Mutation-Positive Erdheim-Chester Disease
 -

Monday, November 06, 2017 11:39:27 AM

Roche (RHHBY) Posts Solid 2017 Sales on Tecentriq & Alecensa - Nasdaq

CNBC

Roche (RHHBY) Posts Solid 2017 Sales on Tecentriq & Alecensa
Nasdaq
During the fourth quarter, Roche obtained FDA approval of a label expansion of a few drugs -Alecensa for first-line treatment in ALK-positive non-small cell lung cancer ("NSCLC"), Zelboraf in Erdheim-Chester disease, Gazyva for untreated advanced ...
Roche 2017 profit falls on impairments


Thursday, February 01, 2018 11:02:20 AM

Deaf pedestrian killed in Newmarket was on way home to care for son - yorkregion.com

yorkregion.com

Deaf pedestrian killed in Newmarket was on way home to care for son
yorkregion.com
She lobbied on behalf of her husband, Tim, who has struggled for the last decade with an extremely rare and debilitating condition called Erdheim-Chester disease (ECD). While studying at Trent University on a Terry Fox scholarship, Pape-Green helped ...


Friday, January 26, 2018 12:04:30 PM

FDA Approves Vemurafenib for Treating Erdheim-Chester Disease - Cancer Network

Cancer Network

FDA Approves Vemurafenib for Treating Erdheim-Chester Disease
Cancer Network
Erdheim–Chester disease originates in the bone marrow and is characterized by the abnormal multiplication of histiocytes, which can invade normal tissue and organs, including the brain, heart, lungs, and others. Each year the disease is estimated to ...


Thursday, November 09, 2017 3:29:33 PM

Erdheim-Chester Disease Treatment Gets FDA Priority Review and Breakthrough Therapy Designation - Rare Disease Report

Erdheim-Chester Disease Treatment Gets FDA Priority Review and Breakthrough Therapy Designation
Rare Disease Report
The U.S. Food and Drug Administration (FDA) has accepted Genentech's supplemental New Drug Application (sNDA) and granted Priority Review for Zelboraf (vemurafenib), a therapy for patients with Erdheim-Chester disease (ECD) with a BRAF V600 mutation ...
FDA Grants Zelboraf Priority Review for Rare Blood Disease


Monday, August 07, 2017 10:29:49 AM

Vemurafenib Effective in BRAF-mutated Erdheim-Chester Disease and Langerhans Cell Histiocytosis - Cancer Therapy Advisor

Cancer Therapy Advisor

Vemurafenib Effective in BRAF-mutated Erdheim-Chester Disease and Langerhans Cell Histiocytosis
Cancer Therapy Advisor
Although patients with ECD and LCH frequently have BRAFV600 mutations and respond to BRAFV600 inhibitor therapy, there was previously a lack of data describing long-term efficacy and safety. Vemurafenib confers a durable and clinically beneficial ...


Thursday, November 30, 2017 1:39:52 PM

Zelboraf approved for use in Erdheim-Chester disease - Medical Xpress

Medical Xpress

Zelboraf approved for use in Erdheim-Chester disease
Medical Xpress
(HealthDay)—Zelboraf (vemurafenib) has been approved by the U.S. Food and Drug Administration as the first drug to treat certain adults patients with Erdheim-Chester disease (ECD). The efficacy of Zelboraf, a kinase inhibitor, was studied in 22 ...


Wednesday, November 08, 2017 3:01:13 PM

Genes associated with Erdheim-Chester disease also linked to cancer - Science Daily

Genes associated with Erdheim-Chester disease also linked to cancer
Science Daily
"The discovery of new genes associated with ECD provides hope for improving the diagnoses of a disease that affects so many parts of the body. We also hope it will help us identify new treatments," said Juvianee I. Estrada-Veras, M.D., clinical ...


Monday, April 03, 2017 12:40:33 PM

High Response Rate in Histiocytic Disease With MEK Inhibition - OncLive

OncLive

High Response Rate in Histiocytic Disease With MEK Inhibition
OncLive
Two additional patients had stable disease (SD), resulting in a clinical benefit rate (CBR) of 100%. Responding patients had a median time to best response of 2.6 months and a median duration of response (DoR) of 6.6 months. “Single-agent cobimetinib ...


Wednesday, January 03, 2018 3:00:33 PM

Share with Others

© Histiocytosis Association, Inc.
332 North Broadway, Pitman, New Jersey  08071 USA
Phone: +1 856-589-6606 | Fax: +1 856-589-6614
| info@histio.org
Privacy | DisclaimerState Fundraising Notices 
Tax ID: 22-2827069 | Contact Us | Site Map
Follow Me on Pinterest   


¿No Habla Inglés? Si usted puede escribirme sus preguntas y preocupaciones a la dirección de correo electrónico: outreach@histio.org. Nosotros podremos responderle tan pronto nos sea possible. Gracias!